DK3898637T3 - Rapamycin-derivater - Google Patents
Rapamycin-derivater Download PDFInfo
- Publication number
- DK3898637T3 DK3898637T3 DK19836546.2T DK19836546T DK3898637T3 DK 3898637 T3 DK3898637 T3 DK 3898637T3 DK 19836546 T DK19836546 T DK 19836546T DK 3898637 T3 DK3898637 T3 DK 3898637T3
- Authority
- DK
- Denmark
- Prior art keywords
- rapamycin derivatives
- rapamycin
- derivatives
- Prior art date
Links
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781242P | 2018-12-18 | 2018-12-18 | |
| PCT/IB2019/060957 WO2020128861A1 (en) | 2018-12-18 | 2019-12-17 | Rapamycin derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3898637T3 true DK3898637T3 (da) | 2025-02-17 |
Family
ID=69165426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19836546.2T DK3898637T3 (da) | 2018-12-18 | 2019-12-17 | Rapamycin-derivater |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12281125B2 (da) |
| EP (1) | EP3898637B1 (da) |
| JP (1) | JP7618553B2 (da) |
| KR (1) | KR102978080B1 (da) |
| CN (1) | CN113260619B (da) |
| AU (1) | AU2019409366B2 (da) |
| BR (1) | BR112021011325A2 (da) |
| CA (1) | CA3122922A1 (da) |
| DK (1) | DK3898637T3 (da) |
| ES (1) | ES3014225T3 (da) |
| FI (1) | FI3898637T3 (da) |
| HR (1) | HRP20250197T1 (da) |
| HU (1) | HUE070859T2 (da) |
| LT (1) | LT3898637T (da) |
| MX (1) | MX2021007247A (da) |
| PL (1) | PL3898637T3 (da) |
| PT (1) | PT3898637T (da) |
| RS (1) | RS66527B1 (da) |
| SI (1) | SI3898637T1 (da) |
| WO (1) | WO2020128861A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY37900A (es) | 2017-09-26 | 2019-04-30 | Novartis Ag | Nuevos derivados de rapamicina |
| US10980784B2 (en) | 2018-06-15 | 2021-04-20 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| CA3127448C (en) | 2019-01-22 | 2024-06-04 | Aeovian Pharmaceuticals, Inc. | Mtorc modulators and uses thereof |
| KR20260115158A (ko) | 2019-03-26 | 2026-07-23 | 노파르티스 아게 | 이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도 |
| EP4069223A4 (en) | 2019-12-05 | 2023-12-20 | Janssen Pharmaceutica NV | RAPAMYCIN ANALOGS AND THEIR USES |
| CN115776907B (zh) | 2020-03-27 | 2025-02-25 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| WO2024211738A1 (en) * | 2023-04-07 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Selective rapamycin analogs and uses thereof |
| GB202415232D0 (en) | 2024-10-16 | 2024-11-27 | Nacamed As | Composition |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5302584A (en) | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| DE69637641D1 (de) | 1995-06-07 | 2008-09-25 | Ariad Gene Therapeutics Inc | Auf rapamycin basierende regulation biologischer vorgänge |
| KR19990022651A (ko) * | 1995-06-07 | 1999-03-25 | 데이비드 엘. 버스테인 | 생물학적 사건에 대한 라파마이신 기재 조절방법 |
| DE69624921T2 (de) | 1995-06-09 | 2003-09-11 | Novartis Ag, Basel | Rapamycinderivate |
| GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| CA2257803C (en) | 1996-07-12 | 2008-12-02 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| IL147803A0 (en) | 1999-08-24 | 2002-08-14 | Ariad Gene Therapeutics Inc | 28-epirapalogs |
| CN1551767A (zh) | 2001-02-19 | 2004-12-01 | ��˹��ŵ�� | 癌症的治疗 |
| EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| GB0601406D0 (en) | 2006-01-24 | 2006-03-08 | Novartis Ag | Organic Compounds |
| US20090023768A1 (en) | 2006-02-24 | 2009-01-22 | Novartis Ag | Rapamycin derivatives for treating neuroblastoma |
| WO2008022256A2 (en) | 2006-08-16 | 2008-02-21 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| WO2011133636A1 (en) | 2010-04-20 | 2011-10-27 | Cedars-Sinai Medical Center | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS |
| EP2670758B1 (en) | 2011-02-04 | 2022-09-28 | Synthon BV | Process for making trisubstituted silyloxyethyl triflates |
| CN103391780B (zh) | 2011-02-16 | 2015-08-19 | 诺瓦提斯公司 | 用于治疗神经变性疾病的治疗剂的组合物 |
| US9174994B2 (en) | 2011-11-23 | 2015-11-03 | Intellikine, Llc | Enhanced treatment regimens using mTor inhibitors |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| EP3109250A1 (en) | 2015-06-23 | 2016-12-28 | Synbias Pharma AG | Method for the synthesis of rapamycin derivatives |
| US10683308B2 (en) * | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| CA3061907A1 (en) | 2017-05-02 | 2018-11-08 | Revolution Medicines, Inc. | Rapamycin analogs as mtor inhibitors |
| UY37900A (es) | 2017-09-26 | 2019-04-30 | Novartis Ag | Nuevos derivados de rapamicina |
| KR20260115158A (ko) | 2019-03-26 | 2026-07-23 | 노파르티스 아게 | 이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도 |
-
2019
- 2019-12-17 LT LTEPPCT/IB2019/060957T patent/LT3898637T/lt unknown
- 2019-12-17 JP JP2021534201A patent/JP7618553B2/ja active Active
- 2019-12-17 DK DK19836546.2T patent/DK3898637T3/da active
- 2019-12-17 FI FIEP19836546.2T patent/FI3898637T3/fi active
- 2019-12-17 HR HRP20250197TT patent/HRP20250197T1/hr unknown
- 2019-12-17 PL PL19836546.2T patent/PL3898637T3/pl unknown
- 2019-12-17 AU AU2019409366A patent/AU2019409366B2/en active Active
- 2019-12-17 SI SI201930897T patent/SI3898637T1/sl unknown
- 2019-12-17 MX MX2021007247A patent/MX2021007247A/es unknown
- 2019-12-17 US US17/414,696 patent/US12281125B2/en active Active
- 2019-12-17 WO PCT/IB2019/060957 patent/WO2020128861A1/en not_active Ceased
- 2019-12-17 BR BR112021011325A patent/BR112021011325A2/pt unknown
- 2019-12-17 ES ES19836546T patent/ES3014225T3/es active Active
- 2019-12-17 PT PT198365462T patent/PT3898637T/pt unknown
- 2019-12-17 CA CA3122922A patent/CA3122922A1/en active Pending
- 2019-12-17 CN CN201980087363.4A patent/CN113260619B/zh active Active
- 2019-12-17 EP EP19836546.2A patent/EP3898637B1/en active Active
- 2019-12-17 HU HUE19836546A patent/HUE070859T2/hu unknown
- 2019-12-17 RS RS20250163A patent/RS66527B1/sr unknown
- 2019-12-17 KR KR1020217022532A patent/KR102978080B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SI3898637T1 (sl) | 2025-04-30 |
| US12281125B2 (en) | 2025-04-22 |
| PL3898637T3 (pl) | 2025-05-19 |
| HRP20250197T1 (hr) | 2025-04-11 |
| HUE070859T2 (hu) | 2025-07-28 |
| EP3898637A1 (en) | 2021-10-27 |
| EP3898637B1 (en) | 2024-11-20 |
| ES3014225T3 (en) | 2025-04-21 |
| PT3898637T (pt) | 2025-02-24 |
| RS66527B1 (sr) | 2025-03-31 |
| JP2022514254A (ja) | 2022-02-10 |
| JP7618553B2 (ja) | 2025-01-21 |
| KR102978080B1 (ko) | 2026-06-17 |
| AU2019409366B2 (en) | 2022-10-27 |
| CN113260619A (zh) | 2021-08-13 |
| FI3898637T3 (fi) | 2025-02-24 |
| US20220064185A1 (en) | 2022-03-03 |
| CN113260619B (zh) | 2026-02-03 |
| KR20210105397A (ko) | 2021-08-26 |
| WO2020128861A1 (en) | 2020-06-25 |
| LT3898637T (lt) | 2025-03-10 |
| MX2021007247A (es) | 2021-07-15 |
| AU2019409366A1 (en) | 2021-06-10 |
| BR112021011325A2 (pt) | 2021-11-16 |
| CA3122922A1 (en) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3958977T (pt) | Derivados de camptotecina | |
| DK3687999T3 (da) | Rapamycinderivater | |
| IL292161A (en) | New methylquinazolinone derivatives | |
| LT3830085T (lt) | Deuterinti lanifibranoro dariniai | |
| DK3642202T3 (da) | Dihydro-pyrrolo-pyridin-derivater | |
| DK4067344T3 (da) | Cycloalkylurinstofderivat | |
| PL3897842T3 (pl) | Pochodne bicykliczne | |
| PL4013751T3 (pl) | Pochodne 2-hydroksycykloalkano-1-karbamoilu | |
| AR120804A1 (es) | Derivados de isoxazolina | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| EP4077334C0 (en) | FUROINDAZOLE DERIVATIVES | |
| LT3457851T (lt) | Sobetiromo dariniai | |
| EP4021904C0 (en) | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | |
| EP3883573A4 (en) | DYRK1A MACROCYCLIC INHIBITORS | |
| LT3402792T (lt) | Chinolin-2-ono dariniai | |
| PL3898637T3 (pl) | Pochodne rapamycyny | |
| EP3885347A4 (en) | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | |
| DK3823970T3 (da) | Yderligere substituerede triazoloquinoxalinderivater | |
| EP3884940A4 (en) | Novel imidazole derivative | |
| PT3796975T (pt) | Derivados de sulfonilaminobenzamida | |
| DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
| DK3652176T3 (da) | Substituerede xanthinderivater | |
| EP3850168C0 (fr) | Elément de construction | |
| DK3645513T3 (da) | Benzazepinderivater | |
| EP3590944A4 (en) | AZETIDINE DERIVATIVE |